More than 40% of Americans are obese, according to the Centers for Disease Control and Prevention (CDC). And the epidemic isn ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

After interviewing dozens of people on weight loss drugs like Zepbound and Ozempic, my view of GLP-1s has completely changed ...

A recent study discovered that individuals using GLP-1 medications may develop severe acid reflux.Researchers discovered that ...

As GLP-1-based drugs like semaglutide gain popularity, new insights highlight how gut health, diet, protein, and sleep can ...

Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

GLP-1 weight-loss drugs are changing how people date and connect. In a nationally representative survey of 2,000 single U.S.

The intense demand for GLP-1 agonists stems from their proven efficacy in managing type 2 diabetes and, increasingly, in facilitating significant weight loss. However, patients often face substantial ...

People using GLP-1 medications are more likely to suffer severe acid reflux, a new study suggests. Researchers found patients ...

Lotte Bjerre Knudsen, Chief Scientific Adviser for Research at Danish pharma giant Novo Nordisk, speaks about GLP-1-based ...

In this Review, the possibilities for utilizing GLP-1 receptor agonists in individualized treatment for type 2 diabetes mellitus are discussed. The currently available compounds are evaluated in ...